Amylyx Pharmaceuticals Q4 net loss beats estimates
Overview
Pharmaceutical firm's Q4 loss per share beat analyst expectations
Net loss for Q4 beat analyst estimates
Company expects cash runway to fund operations through 2028
Outlook
Company expects topline data from Phase 3 LUCIDITY trial in Q3 2026
Amylyx plans potential commercialization of avexitide in 2027
Company targets IND submission for AMX0318 in 2027
Result Drivers
AVEXITIDE DEVELOPMENT - Increased spending on avexitide for PBH offset decrease in R&D expenses
Company press release: ID:nBwbp8fZXa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 EPS | Beat | -$0.30 | -$0.36 (10 Analysts) |
Q4 Net Income | Beat | -$33 mln | -$37.05 mln (9 Analysts) |
Q4 Operating Income | Beat | -$36.61 mln | -$40.37 mln (10 Analysts) |
Q4 Pretax Profit | Beat | -$32.95 mln | -$39.01 mln (6 Analysts) |
Q4 Cash & Investments |
| $317 mln |
|
Q4 Operating Expenses |
| $36.61 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $20.00, about 30.7% above its March 2 closing price of $15.30
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
Related Articles
Spot Silver Prices Volatile, Losses Narrow After 7% Plunge, Has Safe-Haven and Industrial Narrative Failed?
TradingKey - During the Asian trading session, spot silver's intraday decline widened to as much as 7%, reaching $83.05/oz, before subsequently narrowing. As of press time, silver was trading at $85.8/oz. Influenced by recent severe tensions in the Middle East and a complex, volatile international landscape, global commodities—particularly pure benzene, liquefied petroleum gas (LPG), ethylene glycol, styrene, and polypropylene—have experienced significant volatility.
Bitcoin Stuck in Range Struggle, Can US-Iran Conflict Help a Breakout?
As the US-Iran conflict continues to escalate, Bitcoin prices remain range-bound and are losing their war premium.
JPMorgan Warns Hormuz Blockade Risks Oil Shutdown in 25 Days, But How Will the US-Iran Conflict Shape Global Oil Prices?
TradingKey - Following the announcement on the night of February 28 banning all vessels from passing through the Strait of Hormuz, JPMorgan Chase issued a warning: if the Strait of Hormuz is completely blocked, the combined onshore and offshore storage capacity of Middle Eastern oil-producing nation
US-Iran Conflict Ignites, Global Arms Race Heats Up, Will Defense Stocks See a New Round of Gains?
TradingKey - On February 28 local time, the United States and Israel launched joint large-scale airstrikes against Iran, targeting its nuclear facilities, missile industry, and naval forces. This marks another sharp escalation in the conflict following the US military strikes on Iranian nuclear facilities in June last year. The military operation not only exacerbates already strained geopolitical tensions but has also sent shockwaves through global capital markets, which is expected to further boost defense stocks.
The Hyperliquid Phenomenon: HYPE Ecosystem’s Path to $250
Explore the Hyperliquid (HYPE) 2026 outlook as it evolves from a high-speed DEX into a powerful Layer 1 ecosystem. This analysis breaks down the $2.95 trillion trading volume, the impact of the HIP-4 prediction market launch, and the HYPE token's technical resilience at the $31.77 level amidst globa
